ENGN advances detalimogene voraplasmid toward pivotal data and FDA filing
ENGN’s detalimogene voraplasmid, a non-viral gene therapy for BCG-unresponsive NMIBC, is nearing pivotal data and an FDA filing expected by year-end, with interim efficacy and tolerability cited as strong.